IRIDEX Corporation
IRIDEX Corporation (Nasdaq: IRIX) develops and commercializes ophthalmic medical technology used to treat sight-threatening conditions, including glaucoma and retinal diseases. Its products include laser consoles, delivery devices and single-use probes, incorporating MicroPulse, Endpoint Management and… From the company’s description.
Over the twelve months to Jul 4, 2026, IRIDEX Corporation reported revenue of $51.57M, up 3.7% from a year earlier, and a net loss of $3.55M. Its operating margin was −5.4%, and operations used $1.73M in cash. In fiscal 2025, it reported revenue of $52.67M, up 8.2% from fiscal 2024, and a net loss of $4.44M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IRIDEX Corporation does
In the company’s own words
IRIDEX Corporation (Nasdaq: IRIX) develops and commercializes ophthalmic medical technology used to treat sight-threatening conditions, including glaucoma and retinal diseases. Its products include laser consoles, delivery devices and single-use probes, incorporating MicroPulse, Endpoint Management and pattern-scanning technologies alongside continuous-wave laser treatment. Product lines include the Cyclo G6, IQ, PASCAL and OcuLight laser systems, and MicroPulse P3, G-Probe and EndoProbe devices. Customers include ophthalmologists, hospitals, ambulatory surgical centers, clinics, research and teaching hospitals, government installations and veterinary practices. IRIDEX sells through a direct sales force in the United States and Germany and through distributors in many other international markets. Revenue also comes from consumables, equipment repairs and service contracts. The company reports its business as a single operating segment; fiscal 2025 revenue was $52.7 million, and international sales represented 55.9% of revenue. IRIDEX was incorporated in 1989 as IRIS Medical Instruments and adopted its current name in 1996. Its website is www.Iridex.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- MOUNTAIN VIEW, CA
- Fiscal year end
- January
- CIK
- 1006045
- SIC
- 3845
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IRIDEX Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · IRIDEX Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IRIDEX Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IRIDEX Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IRIDEX Corporation's last four quarterly filings that the numbers alone won't show?”